New Member Spotlight: Seda Pharmaceutical Development Services
We warmly welcome Seda Pharmaceutical Development Services as a new member of our life science park, located in our coworking space in The Spark building!
Seda Pharmaceutical Development Services accelerate drug development programmes through stage-appropriate support. Serving clients across the world, Seda offers an integrated suite of services spanning pre-formulation, formulation development, analytical sciences, DMPK and clinical pharmacology evaluation, MIDD/quantitative modelling, clinical manufacturing, regulatory CMC and lifecycle optimisation.
We asked Seda's Helena Engman, Senior Principal Scientist, three key questions to highlight what makes them a trusted and versatile life science partner:
How can the life science community in southern Sweden benefit from your membership at Medicon Village?
– Seda brings together deep scientific understanding and practical development experience. Our clients value that combination because it helps them move forward with clarity and confidence.
– We deliver a full continuum of development services – from understanding molecular behaviour through to formulation selection, process development, PK/PD-driven dose design and clinical supply readiness. Our multi-disciplinary expertise enables companies to accelerate development timelines, avoid common pitfalls and make data-driven decisions early – especially important for challenging molecules, accelerated clinical pathways and complex therapeutic modalities.
– With in-house DMPK and clinical pharmacology capability, we support clients in interpreting preclinical and early clinical data, defining translational strategies and applying quantitative modelling to guide decision-making from first‑in‑human through to late-stage development and market application.
– Whether partnering with emerging biotechs entering the clinic for the first time or supporting global pharma on late‑stage programmes, we provide tailored, risk-based strategies that balance scientific rigour with commercial pragmatism.
What are your major challenges in the coming year to meet market demands and trends?
– We work as an extension of our clients’ teams – closely, transparently, and with a shared commitment to delivering meaningful progress. To highlight is our collaborative development model, where scientific experts integrate directly with client teams to co-design approaches, troubleshoot challenges and build compelling CMC narratives.
– Our strength lies in its integrated expertise across formulation, drug delivery, biopharmaceutics, analytical sciences, DMPK, clinical pharmacology and quantitative modelling. This enables the team to address the root causes of poor solubility, instability, low bioavailability, or challenging PK/PD behaviour.
– A key differentiator is our model-informed development capability, where DMPK and clinical pharmacology insights are combined with predictive tools and experimental evidence to guide formulation selection, dose optimisation and clinical study design thus reducing uncertainty and strengthening development packages.
– Above all, we are scientifically curious, transparent, and committed to quality, ensuring that every recommendation is robust, evidence-based and aligned with regulatory expectations.
What challenges and opportunities do you see in the coming year?
– Molecules are becoming more complex and the expectations around data packages, mechanistic justification and accelerated development are rising. This creates both challenges and exciting opportunities.
– I note a growing demand for more predictive development approaches, particularly those that integrate DMPK, clinical pharmacology and MIDD, to support accelerated or adaptive clinical pathways.
– As organisations face increasing pressure to generate robust CMC, biopharmaceutics, and translational data earlier, we continue to expand our capabilities to support partners with modelling, formulation innovation and clinical manufacturing strategies that enable confident progression and help to navigate an evolving scientific and regulatory landscape.
– Our focus is on remaining agile, science‑driven, and deeply collaborative. Whether a client needs early mechanistic insight, translational support, or late-stage CMC strategy, Seda is structured to meet them where they are and move with them as they grow.
For more information on how Seda Pharmaceutical Development Services can support your next project, visit Seda Pharmaceutical Development Services' profile on our website or the Seda Pharmaceutical Development Services website.